← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
76	76 Celularity CELU $42.5M	–	–	–	–
77	77 Creative Medical Technology CELZ $6.07M	–	–	–	–
78	78 DELISTED CERo Therapeutics CERO	–	–	–	–
79	79 Calidi Biotherapeutics CLDI $2.3M	–	–	–	–
80	80 Cellectis CLLS $111M	–	–	–	–
81	81 DELISTED Centogene N.V. Common Shares CNTG	–	–	–	–
82	82 Coya Therapeutics COYA $103M	–	–	–	–
83	83 Caribou Biosciences CRBU $48M	–	–	–	–
84	84 DELISTED CARGO Therapeutics CRGX	–	–	–	–
85	85 CRISPR Therapeutics CRSP $4.94B	–	–	–	–
86	86 DELISTED CATALENT, INC. CTLT	–	–	–	–
87	CYAD 87 DELISTED Celyad Oncology SA American Depositary Shares CYAD	–	–	–	–
88	DBTX 88 DELISTED Decibel Therapeutics, Inc. Common Stock DBTX	–	–	–	–
89	89 DELISTED DermTech, Inc. Common Stock DMTK	–	–	–	–
90	90 Ginkgo Bioworks DNA $772M	–	–	–	–
91	91 Design Therapeutics DSGN $628M	–	–	–	–
92	92 Precision BioSciences DTIL $167M	–	–	–	–
93	93 Editas Medicine EDIT $366M	–	–	–	–
94	94 enGene Therapeutics ENGN $113M	–	–	–	–
95	95 Enlivex Ltd ENLV $4.36M	–	–	–	–
96	96 Estrella Immunopharma ESLA $14.3M	–	–	–	–
97	97 FibroBiologics FBLG $7.08M	–	–	–	–
98	98 4D Molecular Therapeutics FDMT $694M	–	–	–	–
99	99 Fulgent Genetics FLGT $587M	–	–	–	–
100	FRLN 100 DELISTED Freeline Therapeutics Holdings plc American Depositary Shares FRLN	–	–	–	–